Exhibit 4.1


 


THE SECURITIES REPRESENTED HEREBY AND ISSUABLE
HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES
LAWS OF APPLICABLE STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED
OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION UNDER SUCH LAWS OR AN
EXEMPTION FROM SUCH REGISTRATION REQUIREMENT. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF
THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND
SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ALL APPLICABLE
STATE SECURITIES LAWS.


 


NILE THERAPEUTICS, INC.


SECURED
CONVERTIBLE PROMISSORY NOTE


 


	Principal Amount:  	$[____________]	Dated:  March 15, 2013
	Original Issue Price:  	$[____________]	 


 


Nile Therapeutics, Inc., a corporation
duly organized and existing under the laws of the State of Delaware (the “Company”), for value received, hereby
promises to pay to [________________] (the “Holder”), the aggregate principal sum of [________________] Dollars
($[____]), without interest, pursuant to the following terms and conditions of this Secured Convertible Promissory Note (“Note”).
Except as expressly provided herein, the term “Dollar” and the sign “$” as used herein shall be deemed
to be references to United States dollars. This Note is one in a series of similar promissory notes (collectively, the “Notes”)
issued by the Company pursuant to a Convertible Note Purchase Agreement dated March 15, 2013 by and among the Company, the Holder
and the other purchasers of the Notes named therein (collectively, the “Holders”) (as amended, modified or otherwise
supplemented from time to time, the “Note Purchase Agreement”). Capitalized terms used herein and not otherwise
defined shall have the meanings given to such terms in the Note Purchase Agreement.


 


1.              Payment Terms.  Subject
to the provisions of Sections 2 and 4 hereof, and unless earlier converted or paid pursuant to this Section 1, the entire outstanding
principal balance hereof shall be due and payable on March 15, 2014 (the “Maturity Date”). The Company may prepay
this Note in whole or in part without penalty upon 30 days’ prior written notice to the Holder; provided, however,
that during such 30-day notice period, the Holder may elect to convert all outstanding principal hereunder into shares of the Company’s
common stock (the “Optional Conversion Shares”) at a conversion price per share equal to the average daily Closing
Price (as defined below) over the ten consecutive trading days preceding the date of such prepayment notice. In order to effect
such conversion, the Holder shall surrender this Note at the offices of the Company. Thereupon, the Company shall promptly issue
and deliver to the Holder a certificate for the number of shares of common stock to which the Holder is entitled hereunder. Any
payments made by the Company with regard to any of the Notes will be made simultaneously with regard to all of the Notes in an
amount prorated among the Notes in proportion to the outstanding principal balances of each of the Notes. Payment of this Note
will be made at the address of Holder as set forth in Section 12 hereof, unless another place of payment shall be specified in
writing by Holder. Payment shall be credited first to any fees and expenses incurred by the Holder related to the collection of
this Note, and thereafter to principal.


 




    	 



    	 



    

 


2.               Change of
Control


 


(a) Upon a Change of
Control (as defined below) in which either (i) the outstanding shares of the Company’s common stock are exchanged for securities
of another corporation, or (ii) the Company issues shares of its common stock, with no securities or other consideration paid or
payable to holders of the Company’s common stock (e.g., a merger transaction in which the Company acquires another corporation
in exchange for shares of the Company’s common stock), then (A) the entire unpaid principal under the Note shall automatically
convert, as of immediately prior to the effective time of the Change of Control, into shares of the Company’s common stock
(the “Mandatory Conversion Shares,” and together with the Optional Conversion Shares, the “Conversion
Shares”) at a conversion price per share equal to the Closing Price on the effective date of the Change of Control, and
(B) the Company shall also issue to the Holder a five-year warrant, in substantially the form of Exhibit A hereto, entitling
the Lender to purchase, at an exercise price equal to the Closing Price on the effective date of the Change of Control, that number
of shares of the Company’s common stock (the “Warrant Shares”) obtained by dividing (a) the sum of the
outstanding principal hereunder by (b) the Closing Price on the effective date of the Change of Control.


 


(b) Upon a Change of
Control other than as described in the preceding paragraph, the Company shall pay to the Holder an amount in cash equal to 175%
of the principal amount then outstanding hereunder. Upon payment of such amount to the Holder, all of the Company’s obligations
hereunder shall be deemed paid and satisfied in full.


 


(c) As used herein,
the term “Change of Control” shall mean the consummation of any transaction or series of related transactions
involving (i) the acquisition by any person or group directly or indirectly (by way of merger, stock purchase or asset transaction)
of beneficial ownership of more than 50% of the total voting power of the Company, (ii) any merger, consolidation, amalgamation,
plan or arrangement, acquisition, business combination or similar transaction in which the holders of common stock of the Company
immediately prior to the transaction, as a group, do not hold securities representing a majority of the outstanding voting power
entitled to elect the board of directors of the surviving entity in such merger, consolidation, amalgamation, plan or arrangement,
acquisition, business combination or similar transaction, or (iii) the sale, assignment, lease, exclusive license or other disposition
of all or substantially all of the Company’s assets.


 


(d) As used herein,
the term “Closing Price” shall mean, with respect to the Company’s common stock on any date of determination,
the closing sale price or, if no closing sale price is reported, the last reported sale price of the shares of the common stock
on the relevant securities exchange on such date, or if the common stock is not listed on a securities exchange, the last quoted
bid price for the common stock in the over-the-counter market as reported by Pink Sheets LLC or similar organization, or, if that
bid price is not available, the market price of the common stock on that date as determined in good faith by the Company’s
Board of Directors.


 




    	- 2 -



    	 



    

 


3.              Security.
This Note is secured by the security interests granted pursuant to the Security Agreement. 


 


4.              Default.


 


(a)            Definition.
Upon any of the following events of default (each, an “Event of Default”), all of the then outstanding principal
amount of this Note shall become immediately due and payable:


 


(i)        the Company fails
to make the payment of principal of the Note when the same becomes due and payable;


 


(ii)       the commencement
by or against the Company of any proceeding in bankruptcy or for dissolution, liquidation, winding-up, composition or other relief
under federal or state bankruptcy laws that has not been dismissed within 30 days of formal service on the Company, or the appointment
of a receiver or trustee for the Company or a substantial part of its property or assets; or


 


(iii)      any debtor or
creditor of the Company obtaining an order authorizing it to take possession of a material portion of the assets of the Company
(including, without limitation, any of the Collateral (as defined in the Security Agreement)).


 


(b)           Remedies
of Holder During the Continuance of an Event of Default. The remedies of the Holder as provided herein shall be cumulative
and concurrent with all other remedies provided by law, in equity or under this Note, the Note Purchase Agreement, or the Security
Agreement and may be pursued singly, successively or together at the sole direction of the Holder and may be exercised as often
as occasion therefor shall arise. No act or omission or commission by the Holder, including specifically, any failure to exercise
any right, remedy or recourse, shall be deemed a waiver or release of the same, such waiver or release to be effective only as
set forth in a written document executed by the Holder and then only to the extent specifically recited therein. A waiver or release
with reference to one event shall not be construed as continuing as a bar to, or as a waiver or release of, any subsequent right,
remedy or recourse as to any subsequent event. The Company hereby waives presentment for payment, notice of nonpayment, protest,
notice of protest and all other notices, filing of suit and diligence in collecting the amounts due under this Note and agrees
that the Holder shall not be required first to initiate any suit or exhaust its remedies against any other person or parties in
order to enforce payment of this Note.


 


5.             Amendment;
Waiver.  The terms of this Note may only be amended, modified or waived by written consent of the Company and the
Requisite Purchasers; provided, however, that neither the prepayment terms pursuant to Section 1 nor this Section 5 may be amended,
modified or waived without the written consent of the Holder. Any amendment, modification or waiver effected in accordance with
this Section 5 shall be binding upon the Company, the Holder and each transferee of this Note.


 




    	- 3 -



    	 



    

 


6.             Fractional
Shares. No fractional shares shall be issued upon conversion of this Note, but in lieu of such fractional
shares the Company shall make a cash payment therefor based on the product resulting from multiplying the Closing Price on the
date of conversion by such fraction.


 


7.             No Waiver.  The
Company agrees that any failure to act or failure to exercise any right or remedy on the part of the registered owner shall not
in any way affect or impair the obligations of the Company or be construed as a waiver by the owner of, or otherwise affect, any
of its rights under this Note.


 


8.             Invalidity.  In
the event any one or more of the provisions of this Note shall for any reason be held to be invalid, illegal or unenforceable,
in whole or in part or in any respect, or in the event that any one or more of the provisions of this Note operate or would prospectively
operate to invalidate this Note, then and in either of those events, such provision or provisions only shall be deemed null and
void and shall not affect any other provision of this Note and the remaining provisions of this Note shall remain operative and
in full force and effect and shall in no way be affected, prejudiced and disturbed thereby. Notwithstanding any provision contained
herein to the contrary, in no event shall the amount paid or agreed to be paid by the Company (or any other person) as a premium
on this Note exceed the highest lawful rate permissible under any law applicable thereto.


 


9.             Governing
Law.  This Note shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware,
without giving effect to the principles of conflict of laws.


 


10.           Waiver
of Jury Trial. EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING
OUT OF THIS NOTE OR THE SUBJECT MATTER HEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES
THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT
CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION
HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO
HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY
AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.


 


11.           Entire Agreement.
This Note, the Note Purchase Agreement and the Security Agreement constitute the full and entire understanding and agreement between
the parties with regard to the subjects hereof and thereof.


 




    	- 4 -



    	 



    

 


12.            Notices.
Any notice required or permitted hereunder shall be given in writing and shall be conclusively deemed effectively given
upon personal delivery or delivery by courier, or on the first (1st) business day after transmission if sent by confirmed facsimile
transmission, or three (3) business days after deposit in U.S. mail, by registered or certified mail, postage prepaid, addressed
as set forth in Section 5.03 of the Note Purchase Agreement. For purposes of this Section 12, a “business day”
means a weekday on which banks are open for general banking business in New York City, New York.


 


[Signature page follows]


 




    	- 5 -



    	 



    

 


IN WITNESS WHEREOF,
this Note has been duly executed and delivered by the Company and the Holder as of the date first written above.


 


	 	NILE THERAPEUTICS, INC.
	 	 	 
	 	By:	 	 
	 	Name:	 
	 	Title:	 


 


	 	HOLDER:	 
	 	 	 
	 	If the Holder is an individual (not a partnership, corporation, etc.):
	 	 	 
	 	 	 
	 	Please Print Name	 
	 	 	 
	 	 	 
	 	Signature	 
	 	 	 
	 	 	 
	 	Please Print Name of Joint Holder (if any)	 
	 	 	 
	 	 	 
	 	Signature	 
	 	 	 
	 	If the Holder is a corporation, partnership or other legal entity:
	 	 	 
	 	 	 
	 	Please Print Name of Entity	 


 


	 	By:	 	 
	 	Name:	 
	 	Title:	 


 


[Signature Page to Secured Convertible
Promissory Note]


 




    	 



    	 



    

 


Exhibit A


 


THE SECURITIES REPRESENTED HEREBY AND
ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR
UNDER THE SECURITIES LAWS OF APPLICABLE STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND
MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS, PURSUANT TO
REGISTRATION UNDER SUCH LAWS OR AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENT. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED
TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN
OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE
WITH THE SECURITIES ACT AND ALL APPLICABLE STATE SECURITIES LAWS.


 


NILE THERAPEUTICS, INC.


 


[FORM OF] WARRANT TO PURCHASE COMMON
STOCK


 


	Warrant No. [2013-XX]	 	Original Issue Date: [DATE]1


 


Nile Therapeutics,
Inc., a Delaware corporation (the “Company”), hereby certifies that, for value received, [_______________]
or its permitted registered assigns (the “Holder”), is entitled to purchase from the Company up to a total of
[________________] ([_____]) shares of common stock, $0.001 par value (the “Common Stock”), of the Company (each
such share, a “Warrant Share” and all such shares, the “Warrant Shares”) at an exercise price
per share equal to $[__]2 (as adjusted from time to time as provided in Section 9 herein, the “Exercise Price”),
at any time and from time to time from on or after the date hereof (the “Trigger Date”) and through and including
5:30 P.M., New York City time, on [DATE]3 (the “Expiration Date”), and subject to the following terms
and conditions:


 


This Warrant (this “Warrant”)
is one of a series of similar warrants issued pursuant to that certain Convertible Note Purchase Agreement dated March 15, 2013,
by and among the Company and the Purchasers identified therein (the “Purchase Agreement”). All such warrants
are referred to herein, collectively, as the “Warrants.”


 


1.            Definitions.
In addition to the terms defined elsewhere in this Warrant, capitalized terms that are not otherwise defined herein have the meanings
given to such terms in the Purchase Agreement.


 







1 To be issued upon a Change of Control as described
in Section 2(a) of the accompanying Note.


2 Exercise Price shall be the Closing Price (as defined
in the accompanying Note) on the effective date of the Change of Control.


3 Expiration Date shall be the five-year anniversary
of the Original Issue Date.


 




    	A-1



    	 



    

 


2.            Registration
of Warrants. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any registered
assignee to which this Warrant is permissibly assigned hereunder) from time to time. The Company may deem and treat the registered
Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.


 


3.            Registration
of Transfers. Subject to the restrictions on transfer set forth in Article 4 of the Purchase Agreement and compliance with
all applicable securities laws, the Company shall register the transfer of all or any portion of this Warrant in the Warrant Register,
upon (i) surrender of this Warrant, with the Form of Assignment attached as Schedule 2 hereto duly completed and signed,
to the Company’s transfer agent or to the Company at its address specified herein and (ii) if the Registration Statement
is not effective, (x) delivery, at the request of the Company, of an opinion of counsel reasonably satisfactory to the Company
to the effect that the transfer of such portion of this Warrant may be made pursuant to an available exemption from the registration
requirements of the Securities Act and all applicable state securities or blue sky laws and (y) delivery by the transferee of
a written statement to the Company making the representations and certifications set forth in Article 4 of the Purchase Agreement,
to the Company at its address specified in the Purchase Agreement. Upon any such registration or transfer, a new warrant to purchase
Common Stock in substantially the form of this Warrant (any such new warrant, a “New Warrant”) evidencing the
portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining portion of
this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the
transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations of a Holder of a Warrant.


 


4.            Exercise
and Duration of Warrants.


 


(a)          All
or any part of this Warrant shall be exercisable by the registered Holder at any time and from time to time on or after the Trigger
Date and through and including 5:30 P.M. New York City time on the Expiration Date. At 5:30 P.M., New York City time, on the Expiration
Date, the portion of this Warrant not exercised prior thereto shall be and become void and of no value and this Warrant shall be
terminated and no longer outstanding;


 


(b)          The
Holder may exercise this Warrant by delivering to the Company (i) an exercise notice, in the form attached as Schedule 1
hereto (the “Exercise Notice”), appropriately completed and duly signed and (ii) payment of the Exercise Price
in immediately available funds for the number of Warrant Shares as to which this Warrant is being exercised, and the date such
items are delivered to the Company (as determined in accordance with the notice provisions hereof) is an “Exercise Date.”
The delivery by (or on behalf of) the Holder of the Exercise Notice and the applicable Exercise Price as provided above shall constitute
the Holder’s certification to the Company that its representations contained in Article 4 of the Purchase Agreement are true
and correct as of the Exercise Date as if remade in their entirety (or, in the case of any transferee Holder that is not a party
to the Purchase Agreement, such transferee Holder’s certification to the Company that such representations are true and correct
as to such assignee Holder as of the Exercise Date). The Holder shall not be required to deliver the original Warrant in order
to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the
original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares.


 




    	A-2



    	 



    

 


5.            Delivery
of Warrant Shares. Upon exercise of this Warrant, the Company shall promptly (but in no event later than three trading
days after the Exercise Date) issue or cause to be issued and cause to be delivered to or upon the written order of the Holder
and in such name or names as the Holder may designate (provided that, if the Registration Statement is not effective and the Holder
directs the Company to deliver a certificate for the Warrant Shares in a name other than that of the Holder, it shall deliver to
the Company on the Exercise Date an opinion of counsel reasonably satisfactory to the Company to the effect that the issuance of
such Warrant Shares in such other name may be made pursuant to an available exemption from the registration requirements of the
Securities Act and all applicable state securities or blue sky laws), a certificate for the Warrant Shares issuable upon such exercise,
free of restrictive legends, unless a registration statement covering the resale of the Warrant Shares and naming the Holder as
a selling stockholder thereunder is not then effective or the Warrant Shares are not freely transferable pursuant to Rule 144 under
the Securities Act pursuant to transactions in which paragraph (c)(1) of such rule do not apply. The Holder, or any person permissibly
so designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares
as of the Exercise Date. If the Warrant Shares are to be issued free of all restrictive legends, the Company shall, upon the written
request of the Holder, use its best efforts to deliver, or cause to be delivered, Warrant Shares hereunder electronically through
The Depository Trust Company or another established clearing corporation performing similar functions, if available; provided,
that, the Company may, but will not be required to, change its transfer agent if its current transfer agent cannot deliver Warrant
Shares electronically through such a clearing corporation.


 


6.            Charges,
Taxes and Expenses. Issuance and delivery of certificates for shares of Common Stock upon exercise of this Warrant shall be
made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense in respect
of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company; provided, however, that
the Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the registration of
any certificates for Warrant Shares or Warrants in a name other than that of the Holder. The Holder shall be responsible for all
other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise
hereof.


 


7.            
Replacement of Warrant. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be
issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant,
but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case) and,
in each case, a customary and reasonable indemnity (which shall not include a surety bond), if requested. Applicants for a New
Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable
third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then
the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company’s obligation to issue
the New Warrant.


 




    	A-3



    	 



    

 


8.            
Reservation of Warrant Shares. The Company covenants that it will at all times reserve and keep available out of the aggregate
of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares
upon exercise of this Warrant as herein provided, the number of Warrant Shares which are then issuable and deliverable upon the
exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the
Holder (taking into account the adjustments and restrictions of Section 9). The Company covenants that all Warrant Shares
so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms
hereof, be duly and validly authorized, issued and fully paid and nonassessable. The Company will take all such action as may be
necessary to assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or
regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Shares may be
listed.


 


9.            Certain
Adjustments. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment
from time to time as set forth in this Section 9.


 


(a)          Stock
Dividends and Splits. If the Company, at any time while this Warrant is outstanding, (i) pays a stock dividend on its Common
Stock or otherwise makes a distribution on any class of capital stock that is payable in shares of Common Stock, (ii) subdivides
its outstanding shares of Common Stock into a larger number of shares, or (iii) combines its outstanding shares of Common Stock
into a smaller number of shares, then in each such case the Exercise Price shall be multiplied by a fraction, the numerator of
which shall be the number of shares of Common Stock outstanding immediately before such event and the denominator of which shall
be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to clause (i) of
this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive
such dividend or distribution, and any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately
after the effective date of such subdivision or combination.


 


(b)          
Fundamental Transactions. If, at any time while this Warrant is outstanding (i) the Company effects any merger or consolidation
of the Company with or into another person, in which the shareholders of the Company as of immediately prior to the transaction
own less than a majority of the outstanding stock of the surviving entity, (ii) the Company effects any sale of all or substantially
all of its assets or a majority of its Common Stock is acquired by a third party, in each case, in one or a series of related transactions,
(iii) any tender offer or exchange offer (whether by the Company or another person) is completed pursuant to which all or substantially
all of the holders of Common Stock are permitted to tender or exchange their shares for other securities, cash or property and
would result in the shareholders of the Company immediately prior to such tender offer or exchange offer owning less than a majority
of the outstanding stock after such tender offer or exchange offer, or (iv) the Company effects any reclassification of the Common
Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other
securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by Section
9(a) above) (in any such case, a “Fundamental Transaction”), then the Holder shall have the right thereafter
to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled
to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction,
the holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant (the “Alternate Consideration”).
The Company shall not effect any such Fundamental Transaction unless prior to or simultaneously with the consummation thereof,
any successor to the Company, surviving entity or the corporation purchasing or otherwise acquiring such assets or other appropriate
corporation or entity shall assume the obligation to deliver to the Holder, such Alternate Consideration as, in accordance with
the foregoing provisions, the Holder may be entitled to purchase and/or receive (as the case may be), and the other obligations
under this Warrant. The provisions of this paragraph (c) shall similarly apply to subsequent transactions analogous to a Fundamental
Transaction.


 




    	A-4



    	 



    

 


(c)          Number
of Warrant Shares. Simultaneously with any adjustment to the Exercise Price pursuant to Subparagraph 9(a), the number of
Warrant Shares that may be purchased upon exercise of this Warrant shall be increased or decreased proportionately, so that after
such adjustment the aggregate Exercise Price payable hereunder for the increased or decreased number of Warrant Shares shall be
the same as the aggregate Exercise Price in effect immediately prior to such adjustment.


 


(d)          Calculations.
All calculations under this Section 9 shall be made to the nearest cent or the nearest 1/100th
of a share, as applicable. The number of shares of Common Stock outstanding at any given time shall not include shares owned or
held by or for the account of the Company, and the sale or issuance of any such shares shall be considered an issue or sale of
Common Stock. 


 


(e)           Notice
of Adjustments. Upon the occurrence of each adjustment pursuant to this Section 9, the Company at its expense will,
at the written request of the Holder, compute such adjustment, in good faith, in accordance with the terms of this Warrant and
prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or
type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions
giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the
Company will deliver a copy of each such certificate to the Holder and to the Company’s transfer agent.


 


10.     
     Payment of Exercise Price. The Holder shall pay the Exercise Price in immediately
available funds.


 


11.      
    No Fractional Shares. No fractional Warrant Shares will be issued in connection with
any exercise of this Warrant. In lieu of any fractional shares which would otherwise be issuable, the number of Warrant
Shares to be issued shall be rounded to the nearest whole number.


 


12.           Notices.
Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall
be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication
is delivered via facsimile at the facsimile number specified in the Purchase Agreement prior to 5:30 p.m. (New York City time)
on a trading day, (ii) the next trading day after the date of transmission, if such notice or communication is delivered via facsimile
at the facsimile number specified in the Purchase Agreement on a day that is not a trading day or later than 5:30 p.m. (New York
City time) on any trading day, (iii) the trading day following the date of mailing, if sent by nationally recognized overnight
courier service specifying next business day delivery, or (iv) upon actual receipt by the party to whom such notice is required
to be given, if by hand delivery. The address and facsimile number of a party for such notices or communications shall be as set
forth in the Purchase Agreement unless changed by such party by two trading days’ prior notice to the other party in accordance
with this Section 12.


 




    	A-5



    	 



    

 


13.      
    Warrant Agent. The Company shall serve as warrant agent under this Warrant. Upon thirty
(30) days’ notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or
any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new
warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all
of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any
further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by
first class mail, postage prepaid) to the Holder at the Holder’s last address as shown on the Warrant Register.


 


14.    
      Miscellaneous.  


 


(a)          The
Holder, solely in such person's capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be
deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to
confer upon the Holder, solely in such person's capacity as the Holder of this Warrant, any of the rights of a stockholder of the
Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification
of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends or subscription
rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such person is then entitled to receive upon
the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities
on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether
such liabilities are asserted by the Company or by creditors of the Company. Notwithstanding this Section 15(a), the Company
shall provide the Holder with copies of the same notices and other information given to the shareholders of the Company, contemporaneously
with the giving thereof to the shareholders.


 


(b)          Subject
to the restrictions on transfer set forth on the first page hereof and in Article 4 of the Purchase Agreement, and compliance with
applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company except
to a successor in the event of a Fundamental Transaction. This Warrant shall be binding on and inure to the benefit of the parties
hereto and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed
to give to any person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this
Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns.


 


(c)          Governing
Law. This Warrant shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without
giving effect to the principles of conflict of laws.


 




    	A-6



    	 



    

 


(d)          Waiver
of Jury Trial. EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT
OF THIS NOTE OR THE SUBJECT MATTER HEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES
THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT
CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION
HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO
HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY
AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.


 


(e)          The
headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any
of the provisions hereof.


 


(f)           In
case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability
of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the parties will
attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor,
and upon so agreeing, shall incorporate such substitute provision in this Warrant.


 


(g)           Except
as otherwise set forth herein, prior to exercise of this Warrant, the Holder hereof shall not, by reason of by being a Holder,
be entitled to any rights of a stockholder with respect to the Warrant Shares.


 


[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK,


SIGNATURE PAGE FOLLOWS]


 




    	A-7



    	 



    

 


IN WITNESS WHEREOF, the Company has caused
this Warrant to be duly executed by its authorized officer as of the date first indicated above.


 


	 	NILE THERAPEUTICS, INC.
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:


 




    	A-8



    	 



    

 


SCHEDULE 1


 


FORM OF EXERCISE NOTICE


 


(To be executed by the Holder to exercise
the right to purchase shares


of Common Stock under the foregoing Warrant)


 


To:        Nile Therapeutics, Inc.


 


(1)         The
undersigned is the Holder of Warrant No. [2013-XX] (the “Warrant”) issued by Nile Therapeutics, Inc. a Delaware corporation
(the “Company”). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth
in the Warrant.


 


(2)         The
undersigned hereby exercises its right to purchase __________ Warrant Shares pursuant to the Warrant.


  


(3)         The
Holder shall pay the sum of $_______ in immediately available funds to the Company in accordance with the terms of the Warrant.


 


(4)         Pursuant
to this Exercise Notice, the Company shall deliver to the Holder _____________ Warrant Shares in accordance with the terms of
the Warrant.


 


Dated:_______________, _____


 


	Name of Holder:  	 	 


 


	By:	 	 
	Name: 	 	 
	Title:	 	 
	(Signature must conform in all respects to name of 	 
	Holder as specified on the face of the Warrant)	 


 




    	A-9



    	 



    

 


SCHEDULE 2


 


NILE THERAPEUTICS, INC.


 


FORM OF ASSIGNMENT


[To be completed and signed only upon transfer
of Warrant]


 


FOR VALUE RECEIVED, the undersigned hereby
sells, assigns and transfers unto                             
(the “Transferee” the right represented by the within Warrant to purchase                 
shares of Common Stock of Nile Therapeutics, Inc. (the “Company”) to which the within Warrant relates and appoints
                            
attorney to transfer said right on the books of the Company with full power of substitution in the premises. In connection therewith,
the undersigned represents, warrants, covenants and agrees to and with the Company that:


 


(a)          the
offer and sale of the Warrant contemplated hereby is being made in compliance with Section 4(1) of the United States Securities
Act of 1933, as amended (the “Securities Act”) or another valid exemption from the registration requirements of Section
5 of the Securities Act and in compliance with all applicable securities laws of the states of the United States;


 


(b)          the
undersigned has not offered to sell the Warrant by any form of general solicitation or general advertising, including, but not
limited to, any advertisement, article, notice or other communication published in any newspaper, magazine or similar media or
broadcast over television or radio, and any seminar or meeting whose attendees have been invited by any general solicitation or
general advertising;


 


(c)          the
undersigned has read the Transferee’s investment letter included herewith, and to its actual knowledge, the statements made
therein are true and correct; and


 


(d)          the
undersigned understands that the Company may condition the transfer of the Warrant contemplated hereby upon the delivery to the
Company by the undersigned or the Transferee, as the case may be, of a written opinion of counsel (which opinion shall be in form,
substance and scope customary for opinions of counsel in comparable transactions) to the effect that such transfer may be made
without registration under the Securities Act and under applicable securities laws of the states of the United States.


 


	Dated: 	 	 	 
	 	 	 	(Signature must conform in all respects to name of holder as specified on the face of the Warrant)


 


	 	Address of Transferee:	 
	 	 	 
	 	 	 
	 	 	 


 


	In the presence of:	 
	 	 


 




    	A-10